Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression.

Lerman I, Ma X, Seger C, Maolake A, Garcia-Hernandez ML, Rangel-Moreno J, Ackerman J, Nastiuk KL, Susiarjo M, Hammes SR.

Mol Cancer Res. 2019 Apr;17(4):845-859. doi: 10.1158/1541-7786.MCR-18-0638. Epub 2019 Jan 4.

PMID:
30610107
2.

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.

Natsagdorj A, Izumi K, Hiratsuka K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Shigehara K, Kadono Y, Lin WJ, Maolake A, Mizokami A.

Cancer Sci. 2019 Jan;110(1):279-288. doi: 10.1111/cas.13876. Epub 2018 Dec 7.

3.

Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation.

Maolake A, Izumi K, Natsagdorj A, Iwamoto H, Kadomoto S, Makino T, Naito R, Shigehara K, Kadono Y, Hiratsuka K, Wufuer G, Nastiuk KL, Mizokami A.

Cancer Sci. 2018 May;109(5):1524-1531. doi: 10.1111/cas.13586. Epub 2018 Apr 29.

4.

C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment.

Urata S, Izumi K, Hiratsuka K, Maolake A, Natsagdorj A, Shigehara K, Iwamoto H, Kadomoto S, Makino T, Naito R, Kadono Y, Lin WJ, Wufuer G, Narimoto K, Mizokami A.

Cancer Sci. 2018 Mar;109(3):724-731. doi: 10.1111/cas.13494. Epub 2018 Feb 14.

5.

Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.

Maolake A, Izumi K, Shigehara K, Natsagdorj A, Iwamoto H, Kadomoto S, Takezawa Y, Machioka K, Narimoto K, Namiki M, Lin WJ, Wufuer G, Mizokami A.

Oncotarget. 2017 Feb 7;8(6):9739-9751. doi: 10.18632/oncotarget.14185.

6.

Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.

Iwamoto H, Izumi K, Shimura Y, Natsagdorj A, Maolake A, Takezawa Y, Nohara T, Shigehara K, Kadono Y, Mizokami A.

Anticancer Res. 2016 Oct;36(10):5557-5561.

PMID:
27798930
7.

Aplastic anemia associated with severe hemorrhagic cystitis following radiotherapy for prostate cancer.

Nakano T, Izumi K, Maolake A, Natsagdorji A, Iwamoto H, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M.

Mol Clin Oncol. 2016 May;4(5):794-796. Epub 2016 Feb 25.

8.

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.

Izumi K, Mizokami A, Lin HP, Ho HM, Iwamoto H, Maolake A, Natsagdorj A, Kitagawa Y, Kadono Y, Miyamoto H, Huang CK, Namiki M, Lin WJ.

Oncotarget. 2016 Feb 16;7(7):8389-98. doi: 10.18632/oncotarget.6690.

9.

The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.

Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, Ueno S, Kadono Y, Kitagawa Y, Konaka H, Mizokami A, Namiki M.

Prostate. 2015 Jul 1;75(10):1034-42. doi: 10.1002/pros.22985. Epub 2015 Mar 8.

PMID:
25753899
10.

Efficacy of tegafur-uracil in advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy.

Maolake A, Izumi K, Takahashi R, Itai S, Machioka K, Yaegashi H, Nohara T, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M.

Anticancer Res. 2015 Mar;35(3):1603-6.

PMID:
25750316
11.

Effects of bethanechol chloride and distigmine bromide on postvoiding residual volume in patients with underactive bladder.

Izumi K, Maolake A, Maeda Y, Shigehara K, Namiki M.

Minerva Urol Nefrol. 2014 Dec;66(4):241-7.

PMID:
25531193
12.

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.

Izumi K, Itai S, Takahashi Y, Maolake A, Namiki M.

Oncol Lett. 2014 Jul;8(1):305-308. Epub 2014 Apr 11.

13.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1413-9. doi: 10.1007/s00432-014-1681-8. Epub 2014 Apr 19.

PMID:
24747988
14.

Factors predictive of oncological outcome after nephroureterectomy: comparison between laparoscopic and open procedures.

Izumi K, Itai S, Takahashi Y, Takahashi R, Maolake A, Ofude M, Ueno S, Kadono Y, Kitagawa Y, Konaka H, Mizokami A, Namiki M.

Anticancer Res. 2013 Dec;33(12):5501-6.

PMID:
24324088

Supplemental Content

Loading ...
Support Center